XBiotech to Begin Constructing New R&D Facility on Its 48-acre Campus
XBiotech to Begin Constructing New R&D Facility on Its 48-acre Campus
The new four-story building, to be located close to the existing 46,000 ft2 manufacturing and R&D facility, will provide key infrastructure to support commercialization plans for the company's Natrunix rheumatology program. The new 46,000+ft2 facility will house clinical and medical operations, commercialization teams, and even incorporate wet laboratories, especially to enable ongoing infectious disease programs. In keeping with XBiotech's desire to preserve the woodlands nature on the 48 acre campus, a subterranean parking garage is being constructed to minimize footprint and ecological impact of the new structure.
Architectural Rendition of XBiotech's Planned R&D Facility
xBiotech计划研发设施的建筑再现
Architectural Rendition of XBiotech's Planned R&D Facility
xBiotech计划研发设施的建筑再现
AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. today announced that it plans to expand it's campus headquarters with the construction of a new, state-of-the-art research and development facility. XBiotech has received City of Austin approval to begin excavation for site preparation and groundwork is expected to begin 1st quarter 2024.
得克萨斯州奥斯汀，2024年1月4日（GLOBE NEWSWIRE）——xBiotech Inc.今天宣布，计划通过建造一座新的、最先进的研发设施来扩建其园区总部。xBiotech已获得奥斯汀市的批准，可以开始挖掘以进行场地准备，基础工作预计将开始 1st 2024 年季度。
The new four-story building, to be located close to the existing 46,000 ft2 manufacturing and R&D facility, will provide key infrastructure to support commercialization plans for the company's Natrunix rheumatology program. The new 46,000+ft2 facility will house clinical and medical operations, commercialization teams, and even incorporate wet laboratories, especially to enable ongoing infectious disease programs. In keeping with XBiotech's desire to preserve the woodlands nature on the 48 acre campus, a subterranean parking garage is being constructed to minimize footprint and ecological impact of the new structure.
这座新的四层楼建筑将位于现有的46,000英尺附近2 制造和研发设施，将提供关键基础设施，以支持该公司Natrunix风湿病学计划的商业化计划。全新 46,000 英尺以上2 该设施将容纳临床和医疗业务、商业化团队，甚至包括湿式实验室，特别是为了支持正在进行的传染病项目。为了满足xBiotech在占地48英亩的校园中保护林地自然的愿望，正在建造一个地下停车场，以最大限度地减少新建筑的占地面积和生态影响。
John Simard, President and CEO of XBiotech commented, "We are excited to begin construction of what will be a unique and remarkable R&D facility. It will add significant operational capability to our existing manufacturing and R&D operations on the campus, and will create among the most capable biotechnology operations in Texas."
xBiotech总裁兼首席执行官约翰·西玛德评论说：“我们很高兴开始建造一个独特而卓越的研发设施。它将为我们在园区内现有的制造和研发业务增加显著的运营能力，并将成为德克萨斯州最有能力的生物技术企业之一。”
About XBiotech
XBiotech is pioneering the discovery and development of targeted antibodies based on its True Human technology. The company's mission is to rethink the way antibody medicines are discovered and commercialized by advancing its robust pipeline of truly natural human antibodies for treating serious diseases such as inflammatory conditions like rheumatology, infectious disease, cardiovascular disease and cancer. XBiotech has several candidate products including Natrunix. Cloned from individual donors who possess natural immunity against certain targeted diseases, XBiotech's pipeline of True Human antibodies are intended to deliver unmatched safety and efficacy. Located just minutes from downtown Austin, the XBiotech campus headquarters includes GMP manufacturing facilities, research and testing laboratories, infectious disease research facilities, and quality control and clinical operations. For more information, visit www.xbiotech.com.
关于 xBiotech
xBiotech在基于其真人技术的基础上率先发现和开发靶向抗体。该公司的使命是通过推进其强大的产品线，重新思考抗体药物的发现和商业化的方式 真的 天然的人体抗体，用于治疗严重疾病，例如风湿病、传染病、心血管疾病和癌症等炎症性疾病。xBiotech有几种候选产品，包括Natrunix。xBiotech的True Human抗体产品线从对某些靶向疾病具有自然免疫力的个人捐赠者中克隆而来，旨在提供无与伦比的安全性和有效性。xBiotech园区总部距奥斯汀市中心仅数分钟路程，包括GMP制造设施、研究和测试实验室、传染病研究设施以及质量控制和临床运营。欲了解更多信息，请访问 www.xbiotech.com。
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
关于前瞻性陈述的警示说明
本新闻稿包含前瞻性陈述，包括有关管理层信念和期望的声明，这些声明涉及重大风险和不确定性。前瞻性陈述在预测未来业绩和条件时存在固有的风险和不确定性，这些风险和不确定性可能导致实际结果与这些前瞻性陈述中的预测存在重大差异。这些风险和不确定性受我们在美国证券交易委员会某些文件的 “风险因素” 部分中披露的约束。我们在本新闻稿中所作的任何前瞻性陈述仅代表截至本新闻稿发布之日。在本新闻稿发布之日之后，无论是由于新信息、未来事件还是其他原因，我们都没有义务更新我们的前瞻性陈述。
Contact
联系我们
Wenyi Wei
wwei@xbiotech.com
Tel. 737-207-4600
魏文义
wwei@xbiotech.com
电话：737-207-4600
Photos accompanying this announcement are available at
本公告附带的照片可在以下网址获得
译文内容由第三方软件翻译。
